These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 24442412)

  • 1. The significance of YKL-40 protein in liver fibrosis.
    Tao H; Yang JJ; Shi KH; Huang C; Zhang L; Lv XW; Li J
    Inflamm Res; 2014 Apr; 63(4):249-54. PubMed ID: 24442412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. YKL-40--an emerging biomarker in cardiovascular disease and diabetes.
    Rathcke CN; Vestergaard H
    Cardiovasc Diabetol; 2009 Nov; 8():61. PubMed ID: 19930630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum YKL-40 is increased in patients with hepatic fibrosis.
    Johansen JS; Christoffersen P; Møller S; Price PA; Henriksen JH; Garbarsch C; Bendtsen F
    J Hepatol; 2000 Jun; 32(6):911-20. PubMed ID: 10898311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum YKL-40 in young patients with β-thalassemia major: Relation to hepatitis C virus infection, liver stiffness by transient elastography and cardiovascular complications.
    El-Asrar MA; Elbarbary NS; Ismail EA; Elshenity AM
    Blood Cells Mol Dis; 2016 Jan; 56(1):1-8. PubMed ID: 26603717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease.
    Saitou Y; Shiraki K; Yamanaka Y; Yamaguchi Y; Kawakita T; Yamamoto N; Sugimoto K; Murata K; Nakano T
    World J Gastroenterol; 2005 Jan; 11(4):476-81. PubMed ID: 15641129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease.
    Nøjgaard C; Johansen JS; Christensen E; Skovgaard LT; Price PA; Becker U;
    J Hepatol; 2003 Aug; 39(2):179-86. PubMed ID: 12873813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chondrex (YKL-40), a potential new serum fibrosis marker in patients with alcoholic liver disease.
    Tran A; Benzaken S; Saint-Paul MC; Guzman-Granier E; Hastier P; Pradier C; Barjoan EM; Demuth N; Longo F; Rampal P
    Eur J Gastroenterol Hepatol; 2000 Sep; 12(9):989-93. PubMed ID: 11007134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased immunohistochemical expression of YKL-40 in the spleen of patients with portal hypertension.
    Wang D; Lu JG; Wang Q; Du XL; Dong R; Wang P; Zhao L; Jiang X; Yuan LJ
    Braz J Med Biol Res; 2012 Mar; 45(3):264-72. PubMed ID: 22267006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma YKL-40: a new potential marker of fibrosis in patients with alcoholic cirrhosis?
    Johansen JS; Møller S; Price PA; Bendtsen F; Junge J; Garbarsch C; Henriksen JH
    Scand J Gastroenterol; 1997 Jun; 32(6):582-90. PubMed ID: 9200292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A functional variation in CHI3L1 is associated with severity of liver fibrosis and YKL-40 serum levels in chronic hepatitis C infection.
    Berres ML; Papen S; Pauels K; Schmitz P; Zaldivar MM; Hellerbrand C; Mueller T; Berg T; Weiskirchen R; Trautwein C; Wasmuth HE
    J Hepatol; 2009 Feb; 50(2):370-6. PubMed ID: 19070929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum biomarkers and transient elastography as predictors of advanced liver fibrosis in a United States cohort: the Boston children's hospital experience.
    Lee CK; Perez-Atayde AR; Mitchell PD; Raza R; Afdhal NH; Jonas MM
    J Pediatr; 2013 Oct; 163(4):1058-64.e2. PubMed ID: 23759423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. YKL-40 and transient elastography, a powerful team to assess hepatic fibrosis.
    Rath T; Roderfeld M; Güler C; Wenzel C; Graf J; Beitinger F; Roeb E; Zachoval R
    Scand J Gastroenterol; 2011 Nov; 46(11):1369-80. PubMed ID: 21905976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased expression of YKL-40, a chitinase-like protein, in serum and lung of patients with idiopathic pulmonary fibrosis.
    Furuhashi K; Suda T; Nakamura Y; Inui N; Hashimoto D; Miwa S; Hayakawa H; Kusagaya H; Nakano Y; Nakamura H; Chida K
    Respir Med; 2010 Aug; 104(8):1204-10. PubMed ID: 20347285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. YKL-40 expression in CD14⁺ liver cells in acute and chronic injury.
    Pizano-Martínez O; Yañez-Sánchez I; Alatorre-Carranza P; Miranda-Díaz A; Ortiz-Lazareno PC; García-Iglesias T; Daneri-Navarro A; Vázquez-Del Mercado M; Fafutis-Morris M; Delgado-Rizo V
    World J Gastroenterol; 2011 Sep; 17(33):3830-5. PubMed ID: 21987626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. YKL-40 and hyaluronic acid (HA) as noninvasive markers of liver fibrosis in kidney transplant patients with HCV chronic infection.
    Schiavon LL; Carvalho-Filho RJ; Narciso-Schiavon JL; Medina-Pestana JO; Lanzoni VP; Ferraz ML; Silva AE
    Scand J Gastroenterol; 2010 May; 45(5):615-22. PubMed ID: 20163287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The chitinase-like protein YKL-40 is not a useful biomarker for severe persistent asthma in children.
    Santos CB; Davidson J; Covar RA; Spahn JD
    Ann Allergy Asthma Immunol; 2014 Sep; 113(3):263-6. PubMed ID: 24954373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The chitinase-like protein YKL-40 modulates cystic fibrosis lung disease.
    Hector A; Kormann MS; Mack I; Latzin P; Casaulta C; Kieninger E; Zhou Z; Yildirim AÖ; Bohla A; Rieber N; Kappler M; Koller B; Eber E; Eickmeier O; Zielen S; Eickelberg O; Griese M; Mall MA; Hartl D
    PLoS One; 2011; 6(9):e24399. PubMed ID: 21949714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of serum levels of YKL-40 and hyaluronic acid in patients with hepatic fibrosis due to schistosomiasis japonica and appraisal of their clinical value.
    Zheng M; Cai WM; Zhao JK; Zhu SM; Liu RH
    Acta Trop; 2005; 96(2-3):148-52. PubMed ID: 16188216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. YKL-40 expression could be a poor prognostic marker in the breast cancer tissue.
    Kang EJ; Jung H; Woo OH; Park KH; Woo SU; Yang DS; Kim AR; Lee JB; Kim YH; Kim JS; Seo JH
    Tumour Biol; 2014 Jan; 35(1):277-86. PubMed ID: 23918300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum YKL-40 as a marker of liver fibrosis in patients with non-alcoholic fatty liver disease.
    Kumagai E; Mano Y; Yoshio S; Shoji H; Sugiyama M; Korenaga M; Ishida T; Arai T; Itokawa N; Atsukawa M; Hyogo H; Chayama K; Ohashi T; Ito K; Yoneda M; Kawaguchi T; Torimura T; Nozaki Y; Watanabe S; Mizokami M; Kanto T
    Sci Rep; 2016 Oct; 6():35282. PubMed ID: 27739482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.